Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.

Abstract

BACKGROUND:

No clinical studies have compared the efficacy of liposomal formulation AMB (L-AMB) and voriconazole (VRC) in the treatment of pulmonary aspergillosis. The aim of this study was to compare the efficacy of L-AMB and VRC in murine pulmonary aspergillosis.

METHODS:

Leucopenic mice were infected intratracheally with Aspergillus fumigatus and treated intravenously with L-AMB (once a day) or VRC (twice a day).

RESULTS:

L-AMB and VRC at a dose of >or=5 and >or=20 mg/kg, respectively, significantly prolonged the survival time of infected mice and reduced the pulmonary fungal burden in comparison with the control group. At the maximum recommended dose for clinical use, 5 mg/kg of L-AMB exhibited greater efficacy than 10 mg/kg of VRC, which achieved an area under the concentration-time curve level equivalent to that of 6 mg/kg (loading dose) in humans, in terms of increasing survival and reducing the fungal burden.

CONCLUSION:

The in vivo efficacy of L-AMB was superior to that of VRC at the maximum recommended dose in a murine pulmonary aspergillosis model.

• Authors: Koji Takemoto, Yutaka Yamamoto, Yutaka Ueda, Katsunori Kanazawa, Koichiro Yoshida, Yoshihito Niki
• Journal: Chemotherapy (Chemotherapy) Vol. 55 Issue 2 Pg. 105-13 ( 2009) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 19151551 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright 2009 S. Karger AG, Basel.

Chemical References

• Antifungal Agents
• Pyrimidines
• Triazoles
• liposomal amphotericin B
• Amphotericin B
• Voriconazole

Topics

• Amphotericin B (therapeutic use)
• Animals
• Antifungal Agents (therapeutic use)
• Aspergillus fumigatus (isolation & purification)
• Disease Models, Animal
• Lung (microbiology)
• Male
• Mice
• Pulmonary Aspergillosis (drug therapy)
• Pyrimidines (pharmacokinetics, therapeutic use)
• Triazoles (pharmacokinetics, therapeutic use)
• Voriconazole